UNSPSC 51142432: Naratriptan hydrochloride

This classification denotes a serotonin agonist with the molecular formula C17H25N3O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10X8X4P12Z, chemically known as 1h-indole-5-ethanesulfonamide, n-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride but more generally known as naratriptan hydrochloride, which bears US NIH Compound Identifier 60875. European Medicines Agency schedules Naratriptan hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14631MIG.

UNSPSC 51142432 Naratriptan hydrochloride is a Commodity code, but the recent state and local opportunities tagged under it show a significant mismatch: the three posted solicitations address naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals with OTC products — none of which are naratriptan-specific supplies. The code shows little relevant recent activity; the opportunities appear to reflect broader pharmaceutical supply and distribution arrangements rather than the specific migraine therapeutic this code nominates.

Issuing bodies across the opportunities span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). The Minnesota RFP, posted January 20, 2026, with proposals due March 26, 2026, represents the most structured recent procurement under this code family, seeking manufacturers of generic multi-source pharmaceuticals and OTC products through three authorized wholesalers with contract terms of two years for new vendors. The Texas HHS RFI, posted April 3, 2026, explores direct-to-manufacturer prescription relationships outside traditional pharmacy benefit manager and group purchasing organization channels. Seminole County's IFB (posted June 30, 2026, due July 26, 2023) procures naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option. Geographic activity concentrates in Florida, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle serving a multi-state footprint. The mismatch between the code's nominal scope and actual procurement activity suggests either miscoding at posting or that naratriptan opportunities are not currently active in state and local markets.